$117.810
-15.351 (-13.03%)At close
Price Predictions
Open in app to unlock longer-horizon forecasts.
GRAL Prediction & Forecast by Similar Chart Analysis
Alphio's GRAL stock price prediction model matches the current Grail Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $117.61 (-0.17%). The 1-week path is $116.97 (-0.71%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
Should I Buy Grail Inc Stock?
Grail Inc (GRAL) is currently trading at $117.81, which is significantly below the average analyst price target of $150. However, the stock has seen a sharp decline of 16.20% over the last five days and has an RSI of 29.27, indicating it is oversold. The recent FDA support for its Galleri test has led to an 80% increase in stock price over the past month, suggesting potential for recovery. The main risk is the uncertainty surrounding insurance coverage for the Galleri test, which could impact profitability.
GRAL stock price ended at $117.81 on Friday, after losing -13.03%
Grail Inc (GRAL) last closed at $117.81, losing -13.03%. These facts feed the 1-day and 1-week GRAL price prediction above.
Forecast Drivers
Grail Inc (GRAL) forecast drivers combine similar chart patterns, seasonality, and moving averages.
Similar patterns
Bullish
Seasonality
Bullish
SMA 20
Bearish
SMA 200
Bullish
Similar Chart Patterns
Stocks whose recent price path most closely matches GRAL, ranked by similarity.
Seasonality analysis for GRAL
Historically the probability of a positive October return for GRAL is 76.27%. December offers the highest probability of a positive month at 100.00%, while March is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.